摘要
为分析真实世界刺五加注射液治疗心血管疾病的联合用药治疗方案,提取全国19家三甲医院信息系统(HIS)数据库中使用刺五加注射液治疗心血管疾病患者的一般信息、中西医诊断信息、医嘱记录,采用Tabu算法挖掘不同子结构之间的关系,并用复杂网络分析将结果可视化。全国19家医院5904例患者纳入分析,优效人群为2595,占44%。刺五加注射液治疗心血管疾病常与西药的抗心绞痛药、抗心律失常药、心血管扩张药、抗血栓药、降血脂药及中药祛瘀剂联合应用,使用频次最高的是单硝酸异山梨酯和中药的速效救心丸。优效人群的联合用药方案中不仅有对症治疗,还有针对基础病的用药,在临床中取得较为理想的疗效。通过对不同子结构之间关系的深入分析,可以为联合用药以及研发用药提供支持和借鉴。
In order to analyze the real-world combined drug treatment protocols of Acanthopanax injection for cardiovascular diseases,general information,traditional Chinese and Western medical diagnosis information,and medical prescription records of patients using Acanthopanax injection for cardiovascular diseases in the hospital information system(HIS)database of 193A hospitals across China were extracted,and the relationship between different substructures was mined using the Tabu algorithm,and the results were visualized using complex network analysis.5904 patients from 19 hospitals across China were included in the analysis,and the superior population was 2595,accounting for 44%.Acanthopanax injection for cardiovascular diseases was often combined with western anti-anginal drugs,antiarrhythmics,cardiovascular dilators,antithrombotics,lipid-lowering drugs and Chinese medicine to dispel blood stasis,and the most frequently used were isosorbide mononitrate and quick-acting cardiac pills of Chinese medicine.The combination drug regimen of the superior population includes not only symptomatic treatment,but also drugs for the underlying disease,which achieve more desirable efficacy in the clinic.The in-depth analysis of the relationship between different substructures can provide support and reference for the combined drug use as well as the development of drug use.
作者
秦腾腾
张平
刘峘
王连心
庄鋆妮
Qin Tengteng;Zhang Ping;Liu Huan;Wang Lianxin;Zhuang Yunni(Institute of Basic Research in Clinical Medicine,China Academy of Chinese Medical Sciences,Beijing 100700,China;Wangjing Hospital of China Academy of Chinese Medical Sciences,Beijing 100102,China;College of Statistics,Renmin University of China,Beijing 100872,China)
出处
《世界科学技术-中医药现代化》
CSCD
北大核心
2021年第2期526-535,共10页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
国家科学技术部国家重点研发计划项目(2018YFC1707400):十种中成药大品种和经典名方上市后治疗重大疾病的循证评价及其效应机制的示范研究,负责人:谢雁鸣。
